MedTrace Logo

Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis

NCT07276425 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2025-12-18

No results posted yet for this study

Summary

With the arrival of dupilumab as the first available targeted therapy for PN, there is an unmet need for real-world data and translational research on the working mechanism of dupilumab on PN, to optimize individualized targeted treatment.

Conditions

  • Prurigo Nodularis (PN)

Interventions

DRUG

Dupilumab

In the Netherlands, the standard care for patients with moderate-to-severe prurigo nodularis who have failed or are contraindicated to conventional systemic immunosuppressive treatments consists of 300 mg of dupilumab administered subcutaneously every two weeks, following a loading dose of 600 mg administered subcutaneously.

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • UMC Utrecht

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2028-06-01
Completion
2028-06-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07276425 on ClinicalTrials.gov